February 2017 FDA Recall Drug by Amerisource Health Services
D-0520-2017 - Failed dissolution specifications

This Class II drug recall was voluntarily initiated by Amerisource Health Services on February 3, 2017 for the product Drug. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0520-2017

Reason for Recall
Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.
Initiated
02-03-2017
Reported
03-22-2017
Quantity
19,393 cartons (581,790 extended release tablets)

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Amerisource Health Services
GlipiZIDE Extended-release tablets, 2.5 mg, 30-count carton (NDC 68084-295-21), Individual dose (NDC 68084-395-11), Rx Only, Packaged and Distributed by American Health Packaging, Columbus, Ohio 43217, NDC 68084-295-21

Batch or Lot Expiration Information

Lot# 160133, 160549 Exp. 08/17
Lot# 162006; Exp. 09/17
Lot# 163348A, 163348B; Exp. 10/17